Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sherri Vesely

Nurse Practitioner, Family Tama, IA Nurse Practitioner

NPI 1053398974 CMS profile 10636867

402 Siegel St, Tama, IA 52339

Open in the dashboard

General payments

$5,222

335 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sherri Vesely of Tama, IA is reported in the CMS Open Payments database as having received $5,222 across 335 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,662 104
2024 General $1,955 131
2023 General $1,212 73
2022 General $376 25
2021 General $18 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sherri Vesely
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Sherri Vesely were reported at $1,662. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Sherri Vesely Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $18 $124 $35–$379 $132
2022 $376 $141 $44–$430 $149
2023 $1,212 $154 $49–$476 $160
2024 $1,955 $165 $51–$504 $164
2025 $1,662 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,014 62 payments
  2. Pfizer Inc. $799 79 payments
  3. AstraZeneca Pharmaceuticals LP $586 23 payments
  4. Lilly USA, LLC $414 27 payments
  5. Amgen Inc. $405 33 payments
  6. Novo Nordisk Inc $311 19 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $269 14 payments
  8. Phathom Pharmaceuticals, Inc. $200 9 payments
  9. Astellas Pharma US Inc $174 7 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $157 10 payments
  11. Other $895 52 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,157 334 payments
  2. Education $65 1 payment
Products named General payments · program years 2021–2025
  1. NURTEC ODT $643 71 payments
  2. UBRELVY $477 30 payments
  3. BREZTRI $450 13 payments
  4. QULIPTA $424 23 payments
  5. ZAVZPRET $399 56 payments
  6. FARXIGA $332 7 payments
  7. Repatha $312 25 payments
  8. AIRSUPRA $278 8 payments
  9. Otezla $276 22 payments
  10. ELIQUIS $245 15 payments
  11. Other $3,563 215 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 142 drugs

Part D claims

8,406

Median for Nurse Practitioner: 389

Drug cost

$1,089,814

Median for Nurse Practitioner: $21,885

Branded share of claims

25.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 254 $306,029
Jardiance Empagliflozin Brand 216 $239,146
Ozempic Semaglutide Brand 135 $151,037
Farxiga Dapagliflozin Propanediol Brand 53 $59,991
Rybelsus Semaglutide Brand 32 $53,146
Trulicity Dulaglutide Brand 35 $37,363
Xarelto Rivaroxaban Brand 37 $34,230
Tresiba Flextouch U-100 Insulin Degludec Brand 21 $21,579
Eliquis Apixaban Brand 33 $20,659
Tresiba Flextouch U-200 Insulin Degludec Brand 19 $18,216

The 10 drugs with the highest cost, of 142 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$11,825

Medicare's payments for the services billed

Medicare patients

199

Average age 73

Services billed

1,279

106 women, 93 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 34%
Diabetes 32%
Chronic kidney disease 30%
Ischemic heart disease 21%
COPD 20%
Depression 20%
Atrial fibrillation 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 38 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Lilly USA, LLC $115
  • Boehringer Ingelheim Pharmaceuticals, Inc. $104
$219 216 —
NURTEC ODT
  • PFIZER INC. $195
$195 — —
ZAVZPRET
  • PFIZER INC. $132
$132 — —
QULIPTA
  • AbbVie, Inc. $110
$110 — —
UBRELVY
  • AbbVie, Inc. $91
$91 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 38 with Patron

Records

335 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record